Global diagnostics company Randox has announced the completion of its acquisition of Cellix, a Dublin-based company that develops microfluidic tools and impedance flow cytometers for cell analysis.
The acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space, aligning with its commitment to personalised medicine and improved preventative healthcare.
“The acquisition of Cellix complements and broadens Randox’s offerings by making flow cytometry more accessible to a wider audience of scientists and clinicians,” said Dr Peter FitzGerald, Managing Director of Randox Laboratories. “We are looking forward to bringing together Cellix’s expertise in cytometry with our dedication to diagnostics and believe this combination will enable us to streamline workflows resulting in better outcomes for patients.”
Vivienne Williams, CEO of Cellix added: “Our team is very excited to be joining forces with Randox to scale access to our technology in the broader scientific community. Cellix’s dedicated team has worked hard developing impedance-based cytometry for cell analysis supported through programs including the Disruptive Technology Innovation Fund. With Randox’s strong global presence and dedication to R&D, we are looking forward to continuing development of our technology and expanding our customer footprint.”
With an established product portfolio of microfluidic solutions for life science research; Cellix recently launched its first product in flow cytometry. The Inish Analyser is a microfluidic impedance-based flow cytometer for cell counting, cell viability and cell membrane analysis for transfection efficiencies.
